In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 2412-58-0, name is 1-Methyl-3,4-dihydroisoquinoline, introducing its new discovery. HPLC of Formula: C10H11N
The design of a recombinant whole-cell catalyst and its utilization in the asymmetric reduction of 1-methyl-3,4-dihydroisoquinoline chosen as a model substrate for cyclic imines is presented. As ?designer cells? E. coli cells bearing the two enzymes imine reductase and glucose dehydrogenase (for in situ-cofactor recycling) were constructed, which turned out to be suitable for the asymmetric reduction of 1-methyl-3,4-dihydroisoquinoline at low biocatalyst loading of 2 g/L up to 10 g/L of lyophilized cells, leading to both high conversion and enantioselectivity of >99% ee of the resulting amine. The stoichiometric reducing agent is readily available D-glucose, and a proof of concept for running the reactions at elevated substrate concentration of up to 100 mM was demonstrated.
We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 2412-58-0, and how the biochemistry of the body works.HPLC of Formula: C10H11N
Reference：
Isoquinoline – Wikipedia,
Isoquinoline | C9H865N – PubChem